The Role of Vitamin D3 Therapy in Pediatric Bronchiectasis Severity (CF versus non-CF Patients)

• 作者: Dina A. Mohamed Heba A. Ali Menna Z. Mahmoud Thrwat E. Deraz
• 来源期刊: 儿科学期刊(英文)
• 学科: 数学
• 关键词: Cystic Fibrosis Non-CF Bronchiectasis Vitamin D3 Supplementation EXACERBATION FEV1
• 年，卷（期）: 2020,（3）
• 页码范围: 521-534
• 页数: 14页
• 分类号: O17

摘要

<strong>Objective:</strong><span style="font-family:Verdana;"> To determine and compare the effect of vitamin D3 supplementation on modifying the disease severity in cystic fibrosis (CF) and non</span><span style="font-family:Verdana;">-</span><span style="font-family:Verdana;">CF bronchiectasis pediatric patients.</span><span style="font-family:""> </span><b><span style="font-family:Verdana;">Methods: </span></b><span style="font-family:Verdana;">A randomized clinical trial evaluating the role of oral vitamin D3 supplementation for six months, was performed in forty patients with CF and non</span><span style="font-family:Verdana;">-</span><span style="font-family:Verdana;">CF bronchiectasis under the age of 18 years with vitamin D deficiency or insufficiency. The primary outcome was to reach the sufficient Vitamin D level, the secondary outcome was to reevaluate bronchiectasis severity by following up the frequency, severity of pulmonary exacerbations and lung function after vitamin D3 supplementation.</span><span style="font-family:""> </span><b><span style="font-family:Verdana;">Results:</span></b><b><span style="font-family:""> </span></b><span style="font-family:Verdana;">Forty patients completed the trial. The percentage of improvement of vitamin D level after vitamin D3 supplementation for six months was significantly higher in CF (88.3%) than non</span><span style="font-family:Verdana;">-</span><span style="font-family:Verdana;">CF bronchiectasis patients (59.82%)</span><span style="font-family:""> </span><span style="font-family:Verdana;">(P =</span><span style="font-family:""> </span><span style="font-family:Verdana;">0.03).</span><span style="font-family:""> </span><span style="font-family:Verdana;">Additionally, moderate to severe pulmonary exacerbations significantly decreased by more than 60%, 45% (P</span><span style="font-family:""> </span><span style="font-family:Verdana;">=</span><span style="font-family:""> </span><span style="font-family:Verdana;">0.001,</span><span style="font-family:""> </sp